Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Abemaciclib as Initial Therapy for HR-positive HER2-negative Metastatic Breast Cancer

Approval is based on results from the MONARCH 3 study
28 Feb 2018
Breast cancer;  Anticancer agents & Biologic therapy

On 26 February 2018, the US Food and Drug Administration (FDA) approved abemaciclib (VERZENIO™, Eli Lilly and Company) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Approval was based on MONARCH 3, a randomised (2:1), double-blinded, placebo-controlled, multicentre clinical trial in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. A total of 493 patients were randomised to receive either abemaciclib 150 mg or placebo orally twice daily, plus physician’s choice of letrozole or anastrozole. The estimated median progression-free survival (PFS) according to RECIST v1.1 was 28.2 months (95% CI: 23.5, Not reached) for patients receiving abemaciclib and 14.8 months (95% CI: 11.2, 19.2) for those receiving placebo (HR 0.540; 95% CI: 0.418, 0.698; p < 0.0001).

The most common adverse reactions in at least 20% of patients receiving abemaciclib in MONARCH 3 and more than 2% higher than the placebo arm were diarrhoea, neutropenia, fatigue, infections, nausea, abdominal pain, anaemia, vomiting, alopecia, decreased appetite, and leukopenia.

The recommended starting dose of abemaciclib in combination with an aromatase inhibitor is 150 mg twice daily orally with or without food.

Full prescribing information is available here.  

FDA granted this application priority review. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System. 

Last update: 28 Feb 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings